본문 바로가기
KERD
논문KCI 등재

Genistein의 Endocannabinoid system (ECS) 활성 유도를 통한 피부염 손상 회복 효과

Genistein Recovers Dermatitis Damage through Endocannabinoid System (ECS) Activity

김기봉|서일복|안상현
대한한방소아과학회 (The Association of Pediatrics of Korean Medicine)|2020.02|대한한방소아과학회지 (The Journal of Pediatrics of Korean Medicine)|제34권 제1호|pp. 37-47|DOI 10.7778/jpkm.2020.34.1.37

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

GenisteinCB1Endocannabinoid system (ECS)dermatitisCB2p-JNK
주제분류한의학

초록

목적: 6주된 생쥐에서 피부염 유발한 후 genistein과 palmitoylethanolamide (PEA)를 투여하여 피부염 손상 회복 효과를 알아보고자 하였다. 방법: 6주된 생쥐를 대조군 (Ctrl), 피부염 유발군 (AcDE), 피부염 유발 후 genistein 투여군 (GsT), 피부염 유발 후 PEA 투여군 (PEAT)으로 나누었다. 각 군에 7마리씩 배정하였다. 피부염 유발 후 투약 3일 후 피부 장벽의 변화를 관찰하였다. 결과: GsT과 PEAT에서는 AcDE에 비해 적은 피부 손상을 보였으며, GsT이 제일 낮은 피부손상을 보였다. CB1와 CB2 발현의 intensity는 AcDE에 비해 GsT (64%, 39%)와 PEAT (38%, 28%)는 증가하였다. E-cadherin 양성반응은 AcDE에서 감소한 반면 GsT (76%)와 PEAT (34%)는 증가하였다. p-JNK 양성반응은 AcDE에서 증가하였고, GsT (60%)와 PEAT (39%)는 감소하였다. Genistein이 투여된 3OGsT와 PEA가 투여된 3OPEAT의 간조직에서 간독성이 관찰되지 않았다결론: Genistein이 Endocannabinoid system (ECS) 활성 유도를 통하여 피부염 손상 회복 효과가 있음을 확인하였다.

Abstract

Objectives: After inducing dermatitis in 6-week-old mice, we tried to find out the effects of recovery in the damaged skin by administering genistein and palmitoylethanolamide (PEA) Methods: The 6-week-old mice were divided into the control group (Ctrl), dermatitis causing group (AcDE), genistein-administered group after the onset of dermatitis (GsT), and PEA-administered group after the onset of dermatitis (PEAT). Seven mice were assigned to each group. Changes in the skin barrier were observed after three days of administration following the onset of dermatitis. Results: In the GsT and PEAT, there was less skin damage compared to the AcDE, and the lowest skin damage showed in the GsT. The intensity of CB1 and CB2 expression was increased by 64% (CB1) and 39% (CB2) in the GsT, and 38% (CB1) and 28% (CB2) in the PEAT compared to the AcDE. The E-catherin positive reaction was decreased in the AcDE, while the E-catherin positive reaction was increased in the GsT (76%) and PEAT (34%). The p-JNK positive reaction was increased in the AcDE, while the p-JNK positive reaction was decreased in the GsT (60%) and PEAT (39%). Toxic Hepatopathy was not observed in the liver tissue of Genistein administered 3OGsT, and PEA administered 3OPEAT. Conclusions: Genistein has recovery effect on dermatitis damage through active induction of the endocannabin system (ECS).

참고문헌 (49)

  1. W. Peng, "Pathogenesis of atopic dermatitis", Clin Exp Allergy, 45(3), pp.566~574 (2015)
  2. K. Kabashima, "New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity", J Dermatol Sci, 70(1), pp.3~11 (2013)
  3. P.M. Elias, "Epidermal pathogenesis of inflammatory dermatoses", Am J Contact Dermat, 10(3), pp.119~126 (1999)
  4. H.Y. Lee, "Improvement of skin barrier dysfunction by Scutellaria baicalensis GEOGI extracts through lactic acid fermentation", J Cosmet Dermatol, 18(1), pp.183~191 (2019)
  5. G. Imokawa, "Decreased Level of Ceramides in Stratum Corneum of Atopic Dermatitis: An Etiologic Factor in Atopic Dry Skin?", J Invest Dermatol, 96(4), pp.523~526 (1991)
  6. J. Manzanares, "Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes", Curr Neuropharmacol, 4(3), pp.239~257 (2006)
  7. P. Pacher, "The endocannabinoid system as an emerging target of pharmacotherapy", Pharmacol Rev, 58(3), pp.389~462 (2006)
  8. L.K. Miller, "The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications", Pharmacol Rev, 63(3), pp.461~470 (2011)
  9. T.A. Luger, "Neuromediators--a crucial component of the skin immune system", J Dermatol Sci, 30(2), pp.87~93 (2002)
  10. M. Maccarrone, "The Endocannabinoid System in Human Keratinocytes: Evidence that anandamide inhibits epidermal differentiation through CB1receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase", J Biol Chem, 278(36), pp.33896~33903 (2003)
  11. M. Karsak, "Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System", Science, 316(5830), pp.1494~1497 (2007)
  12. M.L. Casanova, "Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors", J Clin Invest, 111(1), pp.43~50 (2003)
  13. E. Gaffal, "Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation", J Immunol, 190(10), pp.4929~4936 (2013)
  14. B.K. Srivastava, "Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect", Bioorg Med Chem Lett, 19(9), pp.2546~2550 (2009)
  15. N. Dobrosi, "Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling", FASEB J, 22(10), pp.3685~3695 (2008)
  16. J.M. Walker, "Cannabinoid mechanisms of pain suppression", Handb Exp Pharmacol, 168, pp.509~554 (2005)
  17. M.D. Jhaveri, "Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain", Br J Pharmacol, 152(5), pp.624~632 (2007)
  18. B.I. Tóth, "Endocannabinoids Modulate Human Epidermal Keratinocyte Proliferation and Survival via the Sequential Engagement of Cannabinoid Receptor-1 and Transient Receptor Potential Vanilloid-1", J Invest Dermatol, 131(5), pp.1095~1104 (2011)
  19. K.F. Tóth, "Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System", Molecules, 24(5), pp.918~ (2019)
  20. S. Li, "Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network", IET Syst Biol, 1(1), pp.51~60 (2007)
  21. R.A. Muluye, "Anti-inflammatory and Antimicrobial Effects of Heat-Clearing Chinese Herbs: A Current Review", J Tradit Complement Med, 4(2), pp.93~98 (2014)
  22. P.S. Qinghu He, "TCM Case Studies:External Medicine" (2014), PEOPLE'S MEDICAL PUBLISHING HOUSE
  23. A.R. Jung, "Douchi (fermented Glycine max Merr.) alleviates atopic dermatitis-like skin lesions in NC", Nga mice by regulation of PKC and IL-4, 2016, pp.16, ~
  24. H.Y. Cha, "Hataedock Treatment Has Preventive Therapeutic Effects in Atopic Dermatitis-Induced NC", Nga Mice under High-Fat Diet Conditions, 2016, pp.2016, 1739760~
  25. 김희연, "Effect of Skin Lipid Barrier Formation on Hataedock Treatment with Douchi", 대한한의학회지, 38(2), pp.41~52 (2017), 대한한의학회[DOI]
  26. 송지훈, "두시를 이용한 하태독법의 NC", Nga 생쥐에서 DNFB로 유발된 피부손상 완화 효과, 2016, pp.30(2), 109~115[DOI]
  27. J.M. McPartland, "Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system", PloS one, 9(3), pp.e89566~ (2014)
  28. V. Di Marzo, "New approaches and challenges to targeting the endocannabinoid system", Nat Rev Drug Discov, 17(9), pp.623~639 (2018)
  29. A. Dizamatova, "A New Prenylated Isoflavonoid From Limonium leptophyllum", Nat Prod Commun, 14(5) (2019)
  30. L. Thors, "Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase", Br J Pharmacol, 160(3), pp.549~560 (2010)
  31. K. Natsuga, "Epidermal barriers", Cold Spring Harb Perspect Med, 4(4), pp.a018218~ (2014)
  32. C. Blanpain, "Epidermal homeostasis: a balancing act of stem cells in the skin", Nat Rev Mol Cell Biol, 10(3), pp.207~217 (2009)
  33. 김정기, "콜라겐 펩타이드의 피부 장벽 보호 효과", 한국식품과학회지, 43(4), pp.458~463 (2011), 한국식품과학회
  34. Kim BB, "7, 3’, 4’-Trihydroxyisoflavone ameliorates the development of Dermatophagoides farinae-induced Atopic Dermatitis in NC", Nga Mice, 2013, pp.2013, 636597~
  35. Irvine AD, "Breaking the (un)sound barrier:filaggrin is a major gene for atopic dermatitis", J Invest Dermatol, 126, pp.1200~1202 (2006)
  36. C.N. Palmer, "Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis", Nat Genet, 38, pp.441~446 (2006)
  37. O'Regan GM, "The role of filaggrin in the atopic diathesis", Clin Exp Allergy, 40, pp.965~972 (2010)
  38. Barnes KC, "An update on the genetics of atopic dermatitis:scratching the surface in 2009", J Allergy Clin Immunol, 125(1), pp.16~29 (2010)
  39. P. Kupczyk, "Cannabinoid system in the skin – a possible target for future therapies in dermatology", Exp Dermatol, 18(8), pp.669~679 (2009)
  40. M. Salzet, "Invertebrate molecular neuroimmune processes", Brain Res Rev, 34(1), pp.69~79 (2000)
  41. H. Yang, "GPR55 - a putative "type 3" cannabinoid receptor in inflammation", J Basic Clin Physiol Pharmacol, 27(3), pp.297~302 (2016)
  42. 남개원, "Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model", Annals of Dermatology, 28(1), pp.22~29 (2016), 대한피부과학회
  43. H.J. Kim, "Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model", Int J Dermatol, 54(10), pp.401~408 (2015)
  44. T. Haruna, "The Inhibitory Effect of S-777469, a Cannabinoid Type 2 Receptor Agonist, on Skin Inflammation in Mice", Pharmacology, 99(5-6), pp.259~267 (2017)
  45. G. Cantarella, "Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells", Biochem Pharmacol, 82(4), pp.380~388 (2011)
  46. J.P. Thiery, "Complex networks orchestrate epithelial-mesenchymal transitions", Nat Rev Mol Cell Biol, 7(2), pp.131~142 (2006)
  47. P.F. Cheung, "Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis", Int Immunol, 22(6), pp.453~467 (2010)
  48. S. Arbabi, "Mitogen-activated protein kinases", Crit Care Med, 30(1 Suppl), pp.s74~s79 (2002)
  49. Q. Tan, "P38", ERK MAPK signaling pathways are involved in the regulation of filaggrin and involucrin by IL-17, 2017, pp.16(6), 8863~8867

관련 논문AI추천

아토피피부염에서 갈근과 두시 복합추출물의 Endocannabinoid system 조절을 통한 염증조절김기봉, 안상현, 천진홍대한한방소아과학회 · 대한한방소아과학회지2025 · 제39권 제1호아토피피부염에서 ECS 조절을 통한 사백산추출물의 염증 완화 효과김기봉, 안상현, 정아람대한한방소아과학회 · 대한한방소아과학회지2022 · 제36권 제3호β-glucan의 Endocannabinoid system 활성을 통한 아토피피부염 유발 상피 염증 억제 효과김기봉, 서일복, 안상현대한한방소아과학회 · 대한한방소아과학회지2020 · 제34권 제4호아토피피부염에서 Endocannabinoid system (ECS) 조절을 통한 백호탕 추출물의 염증 완화 효과김기봉, 안상현, 정아람대한한방소아과학회 · 대한한방소아과학회지2023 · 제37권 제4호아토피피부염에서 갈근황금황련탕 추출물의 ECS 조절을 통한 염증 완화 효과김기봉, 안상현대한한방소아과학회 · 대한한방소아과학회지2021 · 제35권 제4호치자감초시탕 추출물의 Endocannabinoid system 조절을 통한 아토피피부염 염증조절 효과김기봉, 안상현대한한방소아과학회 · 대한한방소아과학회지2024 · 제38권 제4호

이 간행물의 다른 논문 (4건)

소아 야뇨의 한의학적 치료에 대한 국내외 임상연구 동향 - 2000년 이후 발표된 연구를 중심으로 -이유빈, 정아람pp. 1-25대한한방소아과학회지에 게재된 체계적 문헌고찰의 보고 질 및 방법론적 질 평가이주아, 심수보, 이혜림pp. 26-36소아 비출혈의 한약 치료에 대한 임상 연구 동향 - 2000년대 이후 발표된 중국 RCT 연구를 중심으로 -박용석, 이지홍, 신혜진, 장규태pp. 48-60마비사시 소아 환자에 대한 증례 보고 1례김경민, 권지현, 유선애pp. 61-69
원문 보기